<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02466373</url>
  </required_header>
  <id_info>
    <org_study_id>Clonidine kinetics 1.1</org_study_id>
    <nct_id>NCT02466373</nct_id>
  </id_info>
  <brief_title>Pharmacokinetics and Clinical Effects of Escalating Doses of Clonidine in ICU Patients</brief_title>
  <acronym>Clokin1</acronym>
  <official_title>Pharmacokinetics and Clinical Effects of Escalating Doses of Clonidine in ICU Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Deventer Ziekenhuis</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Deventer Ziekenhuis</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is developed for assessing the pharmacodynamic and pharmacokinetic properties of&#xD;
      intravenous (IV) clonidine in critically ill patients on the ICU, and to estimate the optimal&#xD;
      dosing strategy for IV clonidine.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Many patients in intensive care units (ICU's) require sedation and analgesia to tolerate&#xD;
      mechanical ventilation and other ICU procedures. Commonly used GABA-ergic anaesthetics like&#xD;
      propofol, midazolam and morphine have potential adverse effects that may increase morbidity,&#xD;
      prolong ICU stay and provoke delirium. Recent studies have shown that sedation with&#xD;
      alpha-2-adrenergic agonists may lead to a reduction of the total amount of gamma-aminobutyric&#xD;
      acid (GABA) -ergic anaesthetics and reduction of delirium1In clinical practice the&#xD;
      alpha-2-adrenergic agent clonidine is widely used off label as an add-on sedative in&#xD;
      mechanically ventilated patients who suffer from delirium, but there are no large studies&#xD;
      proving that this therapy is effective and safe. Limited information exists on the&#xD;
      pharmacokinetics of iv clonidine, especially in ICU patients. Besides, dosing regimens of&#xD;
      clonidine differ widely among ICU's in the Netherlands, and in the literature.&#xD;
&#xD;
      The sample size required for pharmacokinetic modelling with an acceptable level of precision&#xD;
      is inversely related to the number of blood samplings taken from each individual. Population&#xD;
      pharmacokinetic experiments that have been published have generally used 50 or more subjects.&#xD;
      However, in the investigators study a relatively large number of blood samples are taken (&gt;10&#xD;
      per subject when the protocol is completed, see section 6.3). THe investigators estimate that&#xD;
      sufficient precision can be obtained with a sample size of 24 subjects, generating an&#xD;
      estimated 240 to 360 blood samples.&#xD;
&#xD;
      In a recent publication of a computer simulated population pharmacokinetics of an absorption&#xD;
      model using a design that involved 6 samplings per subject, it was estimated that a&#xD;
      two-compartment first-order model would need 50 subjects (i.e. 300 blood samplings) to obtain&#xD;
      a model with 50% precision and a power of 0.8.&#xD;
&#xD;
      The investigators 24 subjects will be treated with 3 different doses of clonidine (600, 1200&#xD;
      and 1800 µg/day), that is 8 per treatment arm.&#xD;
&#xD;
      On top of this, 8 patients receiving no clonidine will serve as a reference group, in order&#xD;
      to interpret hemodynamic and safety data, and to illustrate dose-response relationships.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2016</start_date>
  <completion_date type="Actual">April 5, 2018</completion_date>
  <primary_completion_date type="Actual">April 5, 2018</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>clonidine plasma concentrations</measure>
    <time_frame>up to 7 days</time_frame>
    <description>pharmacokinetic and pharmacodynamic properties of intravenous clonidine in ICU patients Clonidine plasma concentration at start of infusion at t=2, t=4, t=8 and t=12 h Clonidine plasma concentration during study, once daily Clonidine plasma concentration after stopping infusion at t=ω+8, t=ω+16, t=ω+24 h, and t=ω+48 h (ω= end of infusion).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>heart rate</measure>
    <time_frame>up to 7 days</time_frame>
    <description>Heart rate 2-hrly for the first 12 h, 8-hrly thereafter</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>blood pressure</measure>
    <time_frame>up to 7 days</time_frame>
    <description>Blood pressure 2-hrly for the first 12 h, 8-hrly thereafter</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>delirium</measure>
    <time_frame>up to 7 days</time_frame>
    <description>delirium rating scale, CAM-ICU 3 times daily</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>use of antipsychotics</measure>
    <time_frame>up to 7 days</time_frame>
    <description>additional use of haloperidol or sedatives, measured in total amount during the investigational period</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">32</enrollment>
  <condition>Delirium</condition>
  <condition>Critical Illness</condition>
  <arm_group>
    <arm_group_label>No clonidine</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>No clonidine is administered. The outcome measures are recorded, to compare them with the outcome measures of the other clonidine arms</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Clonidine 600mcg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>4 patients receive 600 µg/day of clonidine without loading schedule. 4 patients receive 600 µg/day of clonidine with a loading schedule of 300 µg in 4 h.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Clonidine 1200mcg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>4 patients receive 1200 µg/day of clonidine without loading schedule.&#xD;
4 patients receive 1200 µg/day of clonidine with a loading schedule of 600 µg in 4 h.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Clonidine 1800mcg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>4 patients receive 1800 µg/day of clonidine without loading schedule.&#xD;
4 patients receive 1800 µg/day of clonidine with a loading schedule of 900 µg in 4 h.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Clonidine (Catapresan®) 0,150 mg/ml, ampoule 1 ml</intervention_name>
    <description>clonidine intravenous</description>
    <arm_group_label>Clonidine 1200mcg</arm_group_label>
    <arm_group_label>Clonidine 1800mcg</arm_group_label>
    <arm_group_label>Clonidine 600mcg</arm_group_label>
    <other_name>Boehringer Ingelheim, RVG 06055</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        In order to be eligible to participate in this study, a subject must be:&#xD;
&#xD;
          -  at least 18 years of age&#xD;
&#xD;
          -  intubated&#xD;
&#xD;
          -  sedated at the start of the study. Because of the high incidence of delirium on the&#xD;
             ICU in all age categories, all age groups &gt; 18 years will be included&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Severe neurotrauma,&#xD;
&#xD;
          -  Severe dementia (living in a nursing home)&#xD;
&#xD;
          -  Inability to speak Dutch or English, which is one of the causes of not being able to&#xD;
             use the CAM-ICU.&#xD;
&#xD;
          -  The use of clonidine during the 96 hours before the start of the study.&#xD;
&#xD;
          -  Bradycardia (&lt;50/min)&#xD;
&#xD;
          -  Severe hypotension (MAP &lt; 65 after volume resuscitation and vasopressors)&#xD;
&#xD;
          -  Pregnancy and lactation (pregnancy test are routinely performed in premenopausal women&#xD;
             on the ICU).&#xD;
&#xD;
          -  Epilepsy&#xD;
&#xD;
          -  Known clonidine intolerance&#xD;
&#xD;
          -  Liver cirrhosis (Child Pugh class C)&#xD;
&#xD;
          -  Recent and acute myocardial infarction&#xD;
&#xD;
          -  Severe heart failure (LVEF &lt; 30%)&#xD;
&#xD;
          -  Second or third degree atrioventricular (AV)-block without a permanent pacemaker&#xD;
&#xD;
          -  Expected transfer to another hospital.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Huub Oever v/d</last_name>
    <role>Principal Investigator</role>
    <affiliation>Deventer Ziekenhuis</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Deventer Hospital</name>
      <address>
        <city>Deventer</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>July 2018</verification_date>
  <study_first_submitted>April 21, 2015</study_first_submitted>
  <study_first_submitted_qc>June 4, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 9, 2015</study_first_posted>
  <last_update_submitted>July 27, 2018</last_update_submitted>
  <last_update_submitted_qc>July 27, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">July 30, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Deventer Ziekenhuis</investigator_affiliation>
    <investigator_full_name>M. Zeeman</investigator_full_name>
    <investigator_title>drs M. Zeeman</investigator_title>
  </responsible_party>
  <keyword>clonidine</keyword>
  <keyword>pharmacodynamics</keyword>
  <keyword>pharmacokinetics</keyword>
  <keyword>intensive care</keyword>
  <keyword>delirium</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Delirium</mesh_term>
    <mesh_term>Critical Illness</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Clonidine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

